Wingenfeld Katja, Whooley Mary A, Neylan Thomas C, Otte Christian, Cohen Beth E
Department of Psychiatry, Charité University Medical School Berlin, Campus Benjamin Franklin, Berlin, Germany.
General Internal Medicine, Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Psychoneuroendocrinology. 2015 Feb;52:83-91. doi: 10.1016/j.psyneuen.2014.10.023. Epub 2014 Nov 5.
Posttraumatic stress disorder (PTSD) is associated with an increased risk of cardiovascular disease and several other chronic illnesses. Alterations in the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis in PTSD might contribute to these associations but findings regarding SNS and HPA activity in PTSD are heterogeneous. We measured 24-h urinary catecholamines and cortisol in a large cohort of adult outpatients recruited from 2 Veterans Affairs medical centers. 24-h urinary norepinephrine, epinephrine, dopamine and cortisol were measured by tandem mass spectrometry. Lifetime and current PTSD were assessed with the Clinician Administered PTSD Scale using DSM-IV-TR criteria. Out of 613 participants, 199 (32.5%) had current PTSD, 100 (16.3%) had lifetime but not current PTSD, and 314 (51.2%) never had PTSD. Patients with current PTSD had significantly higher norepinephrine secretion compared to those without PTSD. Patients in the lifetime PTSD group exhibited lower cortisol values compared to those without PTSD. Participants who never had PTSD showed the lowest norepinephrine and the highest cortisol values. All results remained stable when controlling for potentially confounding variables. This study provides evidence for increased norepinephrine secretion and decreased cortisol in PTSD. Future longitudinal studies are needed to determine whether these changes contribute to adverse health outcomes in patients with PTSD.
创伤后应激障碍(PTSD)与心血管疾病及其他几种慢性疾病的风险增加有关。PTSD患者交感神经系统(SNS)和下丘脑 - 垂体 - 肾上腺(HPA)轴的改变可能导致了这些关联,但关于PTSD患者SNS和HPA活动的研究结果并不一致。我们在从2个退伍军人事务医疗中心招募的一大群成年门诊患者中测量了24小时尿儿茶酚胺和皮质醇。通过串联质谱法测量24小时尿去甲肾上腺素、肾上腺素、多巴胺和皮质醇。使用DSM-IV-TR标准,通过临床医生管理的PTSD量表评估终生和当前的PTSD。在613名参与者中,199名(32.5%)有当前PTSD,100名(16.3%)有终生但非当前PTSD,314名(51.2%)从未患过PTSD。与没有PTSD的患者相比,当前患有PTSD的患者去甲肾上腺素分泌显著更高。终生PTSD组的患者与没有PTSD的患者相比,皮质醇值较低。从未患过PTSD的参与者去甲肾上腺素最低,皮质醇值最高。在控制潜在的混杂变量后,所有结果保持稳定。本研究为PTSD患者去甲肾上腺素分泌增加和皮质醇减少提供了证据。未来需要进行纵向研究,以确定这些变化是否导致PTSD患者出现不良健康后果。